The Summit Score Stratifies Mortality and Morbidity in Chronic Obstructive Pulmonary Disease

References

• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. doi:10.1183/13993003.00214-201728182564
   PubMed Web of Science ®Google Scholar
• FabbriLM, LuppiF, BeghéB, RabeKF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–212. doi:10.1183/09031936.0011430718166598
   PubMed Web of Science ®Google Scholar
• McGarveyLP, JohnM, AndersonJA, ZvarichM, WiseRA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax. 2007;62:411–415. doi:10.1136/thx.2006.07234817311843
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, AndersonJA, CelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonJA, BrookRD, et al.; on behalf of the SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomized controlled trial. Lancet. 2016;387:1817–1826. doi:10.1016/S0140-6736(16)30069-127203508
   PubMed Web of Science ®Google Scholar
• SinDD, WuL, ManSF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–1959. doi:10.1378/chest.127.6.195215947307
   PubMed Web of Science ®Google Scholar
• LeeHM, LeH, LeeBT, LopezVA, WongND. Forced vital capacity paired with Framingham risk score for prediction of all-cause mortality. Eur Respir J. 2010;36(5):1002–1006. doi:10.1183/09031936.0004241020562119
   PubMed Web of Science ®Google Scholar
• SmithLJE, MooreE, AliI, SmeethL, StoneP, QuintJK. Prognostic variables and scores identifying the end of life in COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2017;12:2239–2256. doi:10.2147/COPD.S13786828814852
   PubMed Web of Science ®Google Scholar
• HorneBD, MayHT, MuhlesteinJB, et al. Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med. 2009;122:550–558. doi:10.1016/j.amjmed.2008.10.04319486718
   PubMed Web of Science ®Google Scholar
• HorneBD, HegewaldM, MuhlesteinJB, et al. Pulmonary-specific intermountain risk score predicts all-cause mortality via spirometry, the red cell distribution width, and other laboratory parameters. Respir Care. 2015;60:1314–1323. doi:10.4187/respcare.0337025873741
   PubMed Web of Science ®Google Scholar
• HorneBD, LappéDL, MuhlesteinJB, et al. Repeated measurement of the intermountain risk score enhances prognostication for mortality. PLoS One. 2013;8:e69160. doi:10.1371/journal.pone.006916023874899
   PubMed Web of Science ®Google Scholar
• MajercikS, KnightS, HorneBD. The intermountain risk score predicts mortality in trauma patients. J Crit Care. 2014;29:882.e1-4. doi:10.1016/j.jcrc.2014.03.016
   PubMed Web of Science ®Google Scholar
• RassaAC, HorneBD, McCubreyRO, et al. Novel stratification of mortality risk by kidney disease stage. Am J Nephrol. 2016;42:443–450. doi:10.1159/000443776
   Web of Science ®Google Scholar
• HorneBD, AndersonJL, MuhlesteinJB, RidkerPM, PaynterNP. The complete blood count risk score and its components including the RDW are associated with mortality in the JUPITER Trial. Eur J Prev Cardiol. 2015;22:519–526. doi:10.1177/204748731351934724403296
   PubMed Web of Science ®Google Scholar
• APPR, SangoiMB, de PaivaLG, ParcianelloJ, da SilvaJE, MorescoRN. Complete blood cell count risk score as a predictor of in-hospital mortality and morbidity among patients undergoing cardiac surgery with cardiopulmonary bypass. Int J Cardiol. 2015;187:60–62. doi:10.1016/j.ijcard.2015.03.22725839621
   PubMed Web of Science ®Google Scholar
• HorneBD, MayHT, KfouryAG, et al. The intermountain risk score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. Eur J Heart Fail. 2010;12:1203–1213. doi:10.1093/eurjhf/hfq11520705688
   PubMed Web of Science ®Google Scholar
• HorneBD, RobertsCA, RasmussonKD, et al. Risk score-guided multidisciplinary team-based care for heart failure inpatients is associated with lower 30-day readmission and lower 30-day mortality. Am Heart J. 2020;219:78–88. doi:10.1016/j.ahj.2019.09.00431739181
   PubMed Web of Science ®Google Scholar
• MayHT, AndersonJL, MuhlesteinJB, LappéDL, RonnowBS, HorneBD. Improvement in the predictive ability of the intermountain mortality risk score by adding routinely collected laboratory tests such as albumin, bilirubin, and white cell differential count. Clin Chem Lab Med. 2016;54:1619–1628. doi:10.1515/cclm-2015-125827101550
   PubMed Web of Science ®Google Scholar
• HorneBD, MuhlesteinJB, BhandaryD, et al. Clinically feasible stratification of 1- to 3-year post-myocardial infarction risk. Open Heart. 2018;5:e000723. doi:10.1136/openhrt-2017-00072329531761
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonJ, BrookRD, et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013;41:1017–1022. doi:10.1183/09031936.0008731223018908
   PubMed Web of Science ®Google Scholar
• PuhanMA, Garcia-AymerichJ, FreyM, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374(9691):704–711. doi:10.1016/S0140-6736(09)61301-519716962
   PubMed Web of Science ®Google Scholar
• BlagevDP, CollingridgeDS, ReaS, et al. The Laboratory-based Intermountain Validated Exacerbation (LIVE) score identifies chronic obstructive pulmonary disease patients at high mortality risk. Front Med. 2018;5:173. doi:10.3389/fmed.2018.00173
   Web of Science ®Google Scholar
• SongS, YangPS, KimTH, et al. Relation of chronic obstructive pulmonary disease to cardiovascular disease in the general population. Am J Cardiol. 2017;120:1399–1404. doi:10.1016/j.amjcard.2017.07.03228826898
   PubMed Web of Science ®Google Scholar
• BhattSP, DransfieldMT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res. 2013;162:237–251. doi:10.1016/j.trsl.2013.05.00123727296
   PubMed Web of Science ®Google Scholar
• HøisethAD, NeukammA, KarlssonBD, OmlandT, BrekkePH, SøysethV. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2011;66:775–781. doi:10.1136/thx.2010.15312221653926
   PubMed Web of Science ®Google Scholar
• CelliBR, CoteCG, MarinJM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa02132214999112
   PubMed Web of Science ®Google Scholar
• JonesRC, DonaldsonGC, ChavannesNH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE index. Am J Respir Crit Care Med. 2009;180:1189–1195. doi:10.1164/rccm.200902-0271OC19797160
   PubMed Web of Science ®Google Scholar
• JanuaryCT, WannLS, AlpertJS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071–2104. doi:10.1161/CIR.000000000000004024682348
   PubMed Web of Science ®Google Scholar
• YehRW, SecemskyEA, KereiakesDJ, et al.; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735–1749. doi:10.1001/jama.2016.377527022822
   PubMed Web of Science ®Google Scholar
• BarnesNC, QiuYS, PavordID, et al.; SCO30005 Study Group. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006;173:736–743. doi:10.1164/rccm.200508-1321OC16424444
   PubMed Web of Science ®Google Scholar